{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:25:54Z","timestamp":1787894754154,"version":"build-2784847793"},"reference-count":255,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico (FONDECYT) Chile","award":["1201475"],"award-info":[{"award-number":["1201475"]}]},{"name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico (FONDECYT) Chile","award":["11200858"],"award-info":[{"award-number":["11200858"]}]},{"name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico (FONDECYT) Chile","award":["13220196"],"award-info":[{"award-number":["13220196"]}]},{"name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo (ANID Exploraci\u00f3n)","award":["1201475"],"award-info":[{"award-number":["1201475"]}]},{"name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo (ANID Exploraci\u00f3n)","award":["11200858"],"award-info":[{"award-number":["11200858"]}]},{"name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo (ANID Exploraci\u00f3n)","award":["13220196"],"award-info":[{"award-number":["13220196"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a well-known chronic neurodegenerative disorder that leads to the progressive death of brain cells, resulting in memory loss and the loss of other critical body functions. In March 2019, one of the major pharmaceutical companies and its partners announced that currently, there is no drug to cure AD, and all clinical trials of the new ones have been cancelled, leaving many people without hope. However, despite the clear message and startling reality, the research continued. Finally, in the last two years, the Food and Drug Administration (FDA) approved the first-ever medications to treat Alzheimer\u2019s, aducanumab and lecanemab. Despite researchers\u2019 support of this decision, there are serious concerns about their effectiveness and safety. The validation of aducanumab by the Centers for Medicare and Medicaid Services is still pending, and lecanemab was authorized without considering data from the phase III trials. Furthermore, numerous reports suggest that patients have died when undergoing extended treatment. While there is evidence that aducanumab and lecanemab may provide some relief to those suffering from AD, their impact remains a topic of ongoing research and debate within the medical community. The fact is that even though there are considerable efforts regarding pharmacological treatment, no definitive cure for AD has been found yet. Nevertheless, it is strongly believed that modern nanotechnology holds promising solutions and effective clinical strategies for the development of diagnostic tools and treatments for AD. This review summarizes the major hallmarks of AD, its etiological mechanisms, and challenges. It explores existing diagnostic and therapeutic methods and the potential of nanotechnology-based approaches for recognizing and monitoring patients at risk of irreversible neuronal degeneration. Overall, it provides a broad overview for those interested in the evolving areas of clinical neuroscience, AD, and related nanotechnology. With further research and development, nanotechnology-based approaches may offer new solutions and hope for millions of people affected by this devastating disease.<\/jats:p>","DOI":"10.3390\/cells12232669","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T01:48:45Z","timestamp":1700531325000},"page":"2669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Major Hypotheses of Alzheimer\u2019s Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-0796","authenticated-orcid":false,"given":"C\u00e9sar","family":"C\u00e1ceres","sequence":"first","affiliation":[{"name":"Facultad de Ingenier\u00eda y Ciencias, Universidad Adolfo Ib\u00e1\u00f1ez, Vi\u00f1a del Mar 2562307, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7423-3821","authenticated-orcid":false,"given":"Bernardita","family":"Heusser","sequence":"additional","affiliation":[{"name":"Facultad de Ingenier\u00eda y Ciencias, Universidad Adolfo Ib\u00e1\u00f1ez, Vi\u00f1a del Mar 2562307, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Garnham","sequence":"additional","affiliation":[{"name":"Facultad de Ingenier\u00eda y Ciencias, Universidad Adolfo Ib\u00e1\u00f1ez, Vi\u00f1a del Mar 2562307, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2324-6735","authenticated-orcid":false,"given":"Ewa","family":"Moczko","sequence":"additional","affiliation":[{"name":"Facultad de Ingenier\u00eda y Ciencias, Universidad Adolfo Ib\u00e1\u00f1ez, Vi\u00f1a del Mar 2562307, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fpubh.2016.00159","article-title":"Use Your Words Carefully: What Is a Chronic Disease?","volume":"4","author":"Bernell","year":"2016","journal-title":"Front. Public Health"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dur\u00e3es, F., Pinto, M., and Sousa, E. (2018). Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020044"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer\u2019s Disease Facts and Figures","volume":"18","author":"Gaugler","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"dmm031781","DOI":"10.1242\/dmm.031781","article-title":"Molecular biomarkers of Alzheimer\u2019s disease: Progress and prospects","volume":"11","author":"Lashley","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41582-018-0128-2","article-title":"Deep brain stimulation: Current challenges and future directions","volume":"15","author":"Lozano","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mashal, Y., Abdelhady, H., and Iyer, A.K. (2022). Comparison of Tau and Amyloid-Beta Targeted Immunotherapy Nanoparticles for Alzheimer\u2019s Disease. Biomolecules, 12.","DOI":"10.3390\/biom12071001"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/d41586-021-01763-9","article-title":"Alzheimer\u00b4s Drug Approval Could Affect Other Diseases","volume":"595","author":"Mullard","year":"2021","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A Critical Appraisal of Amyloid-Beta Targeting Therapies for Alzheimer Disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2174\/0929867327666200831140745","article-title":"Tackling Alzheimer\u2019s Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles","volume":"28","author":"Rampa","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/aps.2017.28","article-title":"Amyloid beta: Structure, biology and structure-based therapeutic development","volume":"38","author":"Chen","year":"2017","journal-title":"Acta. Pharmacol. Sin."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Godoy, P.A., Mennickent, D., Cuchillo-Ib\u00e1\u00f1ez, I., Ram\u00edrez-Molina, O., Silva-Grecchi, T., Panes-Fern\u00e1ndez, J., Castro, P., S\u00e1ez-Valero, J., and Fuentealba, J. (2021). Increased P2\u00d72 Receptors Induced by Amyloid-\u03b2 Peptide Participates in the Neurotoxicity in Alzheimer\u2019s Disease. Biomed. Pharmacother., 142.","DOI":"10.1016\/j.biopha.2021.111968"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1021\/acschemneuro.0c00414","article-title":"Gabapentin Inhibits Multiple Steps in the Amyloid Beta Toxicity Cascade","volume":"11","author":"Burgos","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3233\/JAD-151160","article-title":"A Novel Small Molecule Modulator of Amyloid Pathology","volume":"53","author":"Lovell","year":"2016","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1073\/pnas.0813355106","article-title":"Small Molecule Blockers of the Alzheimer A Beta Calcium Channel Potently Protect Neurons from A Beta Cytotoxicity","volume":"106","author":"Diaz","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"135959","DOI":"10.1016\/j.neulet.2021.135959","article-title":"Mini-Review: Amyloid Degradation Toxicity Hypothesis of Alzheimer\u2019s Disease","volume":"756","author":"Zaretsky","year":"2021","journal-title":"Neurosci. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1529\/biophysj.108.135517","article-title":"Efficiency of Histidine-Associating Compounds for Blocking the Alzheimer\u2019s A Beta Channel Activity and Cytotoxicity","volume":"95","author":"Arispe","year":"2008","journal-title":"Biophys. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbamcr.2018.07.018","article-title":"Calcium signaling in Alzheimer\u2019s disease & therapies","volume":"1865","author":"Tong","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) Bioenerg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.neurobiolaging.2013.08.035","article-title":"Nature of the Neurotoxic Membrane Actions of Amyloid-\u03b2 on Hippocampal Neurons in Alzheimer\u2019s Disease","volume":"35","author":"Sepulveda","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Aus\u00f3, E., G\u00f3mez-Vicente, V., and Esquiva, G. (2020). Biomarkers for Alzheimer\u2019s Disease Early Diagnosis. J. Pers. Med., 10.","DOI":"10.3390\/jpm10030114"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.semnuclmed.2020.12.005","article-title":"Advances in Brain Amyloid Imaging","volume":"51","author":"Krishnadas","year":"2021","journal-title":"Semin. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/WCO.0000000000000947","article-title":"Update on neuroimaging in Alzheimer\u2019s disease","volume":"34","author":"Sintini","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/WCO.0000000000000570","article-title":"Alzheimer\u2019s Disease Neuroimaging","volume":"31","author":"Whitwell","year":"2018","journal-title":"Curr. Opin. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s13311-016-0474-y","article-title":"Amyloid Imaging: Poised for Integration into Medical Practice","volume":"14","author":"Anand","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E1799","DOI":"10.1212\/WNL.0000000000012770","article-title":"Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Beta PET Signal","volume":"97","author":"McCarter","year":"2021","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0299-y","article-title":"Diagnosis of Alzheimer\u2019s disease utilizing amyloid and tau as fluid biomarkers","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"106631","DOI":"10.1016\/j.phrs.2022.106631","article-title":"Role of Monomeric Amyloid-Beta in Cognitive Performance in Alzheimer\u2019s Disease: Insights from Clinical Trials with Secretase Inhibitors and Monoclonal Antibodies","volume":"187","author":"Imbimbo","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kim, J., Jeong, M., Stiles, W.R., and Choi, H.S. (2022). Neuroimaging Modalities in Alzheimer\u2019s Disease: Diagnosis and Clinical Features. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23116079"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neuroimage.2019.01.031","article-title":"A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer\u2019s disease","volume":"189","author":"Spasov","year":"2019","journal-title":"NeuroImage"},{"key":"ref_29","first-page":"65","article-title":"Functional Brain Imaging Synthesis Based on Image Decomposition and Kernel Modeling: Application to Neurodegenerative Diseases","volume":"11","author":"Segovia","year":"2017","journal-title":"Front. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neucom.2020.01.053","article-title":"Detecting Alzheimer\u2019s disease Based on 4D fMRI: An exploration under deep learning framework","volume":"388","author":"Li","year":"2020","journal-title":"Neurocomputing"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnhum.2019.00017","article-title":"The Importance of the Validation of M\/EEG With Current Biomarkers in Alzheimer\u2019s Disease","volume":"13","author":"Maestu","year":"2019","journal-title":"Front. Hum. Neurosci."},{"key":"ref_32","first-page":"1","article-title":"Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer\u2019s disease using EEG technology","volume":"15","author":"Jiao","year":"2023","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Monllor, P., Cervera-Ferri, A., Lloret, M.A., Esteve, D., Lopez, B., Leon, J.L., and Lloret, A. (2021). Electroencephalography as a Non-Invasive Biomarker of Alzheimer\u2019s Disease: A Forgotten Candidate to Substitute CSF Molecules?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910889"},{"key":"ref_34","first-page":"704","article-title":"Blood Biomarkers in Alzheimer\u2019s Disease","volume":"36","year":"2021","journal-title":"Neurologia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-021-00451-6","article-title":"A blood-based diagnostic test incorporating plasma A\u03b242\/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: Findings from a multi cohort validity analysis","volume":"16","author":"West","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3233\/JAD-210327","article-title":"Retinal Amyloid Imaging for Screening Alzheimer\u2019s Disease","volume":"83","author":"Tadokoro","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-023-02548-2","article-title":"Retinal pathological features and proteome signatures of Alzheimer\u2019s disease","volume":"145","author":"Koronyo","year":"2023","journal-title":"Acta Neuropathol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gharbiya, M., Visioli, G., Trebbastoni, A., Albanese, G.M., Colardo, M., D\u2019antonio, F., Segatto, M., and Lambiase, A. (2023). Beta-Amyloid Peptide in Tears: An Early Diagnostic Marker of Alzheimer\u2019s Disease Correlated with Choroidal Thickness. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032590"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3233\/JAD-220596","article-title":"Retinal Examinations Provides Early Warning of Alzheimer\u2019s Disease","volume":"90","author":"Xia","year":"2022","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Stanciu, G.D., Ababei, D.C., Rusu, R.N., Bild, V., and Tamba, B.-I. (2022). Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer\u2019s Disease in Relation to Therapeutic Editing Tools. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061270"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1007\/s12035-021-02385-y","article-title":"The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer\u2019s Disease","volume":"58","author":"Xia","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S718","DOI":"10.1192\/j.eurpsy.2021.1902","article-title":"A populational review of the amyloid precursor protein gene mutations relevant to alzheimer\u2019s disease","volume":"64","author":"Balmus","year":"2021","journal-title":"Eur. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"736937","DOI":"10.3389\/fnagi.2021.736937","article-title":"Association Between Plasma Amyloid-Beta and Neuropsychological Performance in Patients With Cognitive Decline. Front","volume":"13","author":"Yun","year":"2021","journal-title":"Aging Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3233\/JAD-220397","article-title":"Mini-Mental State Examination and Montreal Cognitive Assessment as Tools for Following Cognitive Changes in Alzheimer\u2019s Disease Neuroimaging Initiative Participants","volume":"90","author":"Wang","year":"2022","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_45","first-page":"CD010783","article-title":"Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI)","volume":"2021","author":"Smailagic","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fnagi.2019.00211","article-title":"Topographical Heterogeneity of Alzheimer\u2019s Disease Based on MR Imaging, Tau PET, and Amyloid PET","volume":"11","author":"Jeon","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Torteya, A., Trevi\u00f1o, V., and Tamez-Pe\u00f1a, J.G. (2015). Improved Diagnostic Multimodal Biomarkers for Alzheimer\u2019s Disease and Mild Cognitive Impairment. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/961314"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3233\/JAD-191038","article-title":"Predicting Amyloid-Beta Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques","volume":"73","author":"Initi","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"755499","DOI":"10.3389\/fncom.2021.755499","article-title":"Machine Learning to Predict Brain Amyloid Pathology in Pre-dementia Alzheimer\u2019s Disease Using QEEG Features and Genetic Algorithm Heuristic","volume":"15","author":"Kim","year":"2021","journal-title":"Front. Comput. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab-Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer\u2019s Disease","volume":"20","author":"Soderberg","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41582-019-0205-1","article-title":"Alzheimer disease and aducanumab: Adjusting our approach","volume":"15","author":"Selkoe","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Moore, K.B.E., Pirela, J.P.T., and Fortin, J.S. (2022). Revisiting Small Molecule Inhibitors of Amyloid-Beta Aggregation. FASEB J., 36.","DOI":"10.1096\/fasebj.2022.36.S1.0R528"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1002\/chem.201905621","article-title":"Rational Design of a Cocktail of Inhibitors against A Beta Aggregation","volume":"26","author":"Li","year":"2020","journal-title":"Chem. Eur. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","article-title":"The case for low-level BACE1 inhibition for the prevention of Alzheimer disease","volume":"17","author":"McDade","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1101452","DOI":"10.3389\/fphar.2023.1101452","article-title":"Advances in Alzheimer\u2019s Disease\u2019s Pharmacological Treatment","volume":"14","author":"Conti","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mantile, F., and Prisco, A. (2020). Vaccination against Beta-Amyloid as a Strategy for the Prevention of Alzheimer\u2019s Disease. Biology, 9.","DOI":"10.3390\/biology9120425"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/JAD-215145","article-title":"Genetic Therapies for Alzheimer\u2019s Disease: A Scoping Review","volume":"84","author":"Lennon","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.ymthe.2021.02.026","article-title":"Gene Therapy Using A Beta Variants for Amyloid Reduction","volume":"29","author":"Park","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10238-019-00557-8","article-title":"Adeno-associated virus as a gene therapy vector: Strategies to neutralize the neutralizing antibodies","volume":"19","author":"Lotfinia","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9874159","DOI":"10.1155\/2019\/9874159","article-title":"Nutrients in the Prevention of Alzheimer\u2019s Disease","volume":"2019","author":"Cremonini","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Stefaniak, O., Dobrzy\u0144ska, M., Drzyma\u0142a-Czy\u017c, S., and Przys\u0142awski, J. (2022). Diet in the Prevention of Alzheimer\u2019s Disease: Current Knowledge and Future Research Requirements. Nutrients, 14.","DOI":"10.3390\/nu14214564"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/1673-5374.265544","article-title":"Current status and future prospects of stem cell therapy in Alzheimer\u2019s disease","volume":"15","author":"Fu","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-981-15-4370-8_4","article-title":"Stem Cell Therapy for Alzheimer\u2019s Disease","volume":"Volume 1266","author":"Han","year":"2020","journal-title":"Stem Cell-Based Therapy for Neurodegenerative Diseases"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2174\/1567205013666160930113907","article-title":"Therapeutic Noninvasive Brain Stimulation in Alzheimer\u2019s Disease","volume":"14","author":"Gonsalvez","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fnhum.2020.00179","article-title":"Non-invasive Brain Stimulation in Alzheimer\u2019s Disease and Mild Cognitive Impairment\u2014A State-of-the-Art Review on Methodological Characteristics and Stimulation Parameters","volume":"14","author":"Holczer","year":"2020","journal-title":"Front. Hum. Neurosci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Soobiah, C., Tadrous, M., Knowles, S., Blondal, E., Ashoor, H.M., Ghassemi, M., Khan, P.A., Ho, J., Tricco, A.C., and Straus, S.E. (2019). Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer\u2019s Dementia. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215225"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Huang, Y.L., Chang, Y., Liu, L., and Wang, J.X. (2021). Nanomaterials for Modulating the Aggregation of Beta-Amyloid Peptides. Molecules, 26.","DOI":"10.3390\/molecules26144301"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"20894","DOI":"10.1039\/C8NR04506B","article-title":"Impact of nanoparticles on amyloid peptide and protein aggregation: A review with a focus on gold nanoparticles","volume":"10","author":"John","year":"2018","journal-title":"Nanoscale"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19060","DOI":"10.1039\/C5NR06282A","article-title":"Graphene Quantum Dots for the Inhibition of Beta Amyloid Aggregation","volume":"7","author":"Liu","year":"2015","journal-title":"Nanoscale"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.nano.2017.12.006","article-title":"Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer\u2019s disease-like transgenic mouse model","volume":"14","author":"Carradori","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"654611","DOI":"10.3389\/fphar.2021.654611","article-title":"Application of Antibody Fragments Against A Beta With Emphasis on Combined Application With Nanoparticles in Alzheimer\u2019s Disease","volume":"12","author":"Sun","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acschemneuro.1c00035","article-title":"Brain Targeting and A Beta Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP\/PS1 Transgenic Mice","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2174\/13816128113199990068","article-title":"Inhibition of Amyloid-Beta Aggregation in Alzheimer\u2019s Disease","volume":"20","author":"Wang","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1039\/D2PY01217K","article-title":"Bioinspired Synthetic Polymers-Based Inhibitors of Alzheimer\u2019s Amyloid-Beta Peptide Aggregation","volume":"14","author":"Rupali","year":"2023","journal-title":"Polym. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1021\/acsomega.2c06939","article-title":"Role of Metal Cations of Copper, Iron, and Aluminum and Multifunctional Ligands in Alzheimer\u2019s Disease: Experimental and Computational Insights","volume":"8","author":"Chaparro","year":"2023","journal-title":"ACS Omega"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Gao, H., Zheng, W., and Xu, H. (2022). Current understanding of the interactions between metal ions and Apolipoprotein E in Alzheimer\u2019s disease. Neurobiol. Dis., 172.","DOI":"10.1016\/j.nbd.2022.105824"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Poudel, P., and Park, S. (2022). Recent Advances in the Treatment of Alzheimer\u2019s Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14040835"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Teleanu, D.M., Negut, I., Grumezescu, V., Grumezescu, A.M., and Teleanu, R.I. (2019). Nanomaterials for Drug Delivery to the Central Nervous System. Nanomaterials, 9.","DOI":"10.3390\/nano9030371"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.2174\/0929867330666221115103513","article-title":"Recent nanoscale carriers for therapy of Alzheimer\u2019s disease: Current strategies and perspectives","volume":"30","author":"Zakharova","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e2207719","DOI":"10.1002\/adma.202207719","article-title":"A Therapeutic Nanovaccine that Generates Anti-Amyloid Antibodies and Amyloid-specific Regulatory T Cells for Alzheimer\u2019s Disease","volume":"35","author":"Jung","year":"2022","journal-title":"Adv. Mater."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41401-020-0429-z","article-title":"Nanomedicine-based immunotherapy for central nervous system disorders","volume":"41","author":"Hanif","year":"2020","journal-title":"Acta. Pharmacol. Sin."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Teleanu, D.M., Chircov, C., Grumezescu, A.M., Volceanov, A., and Teleanu, R.I. (2019). Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging. Nanomaterials, 9.","DOI":"10.3390\/nano9040542"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccr.2016.04.018","article-title":"Alzheimer\u2019s disease: The use of contrast agents for magnetic resonance imaging to detect amyloid beta peptide inside the brain","volume":"327\u2013328","author":"Salerno","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Cao, Y., and Zhang, R. (2022). The application of nanotechnology in treatment of Alzheimer\u2019s disease. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.1042986"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.molmed.2015.06.001","article-title":"Gene therapy for neurodegenerative diseases","volume":"21","author":"Boulis","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Carneiro, P., Morais, S., and Pereira, M.C. (2019). Nanomaterials towards Biosensing of Alzheimer\u2019s Disease Biomarkers. Nanomaterials, 9.","DOI":"10.3390\/nano9121663"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bios.2016.01.065","article-title":"Nano-biosensors to detect beta-amyloid for Alzheimer\u2019s disease management","volume":"80","author":"Kaushik","year":"2016","journal-title":"Biosens. Bioelectron."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1039\/D2NR05787E","article-title":"A Label-Free Electrochemical Immunosensor Based on Au-BSN-RGO for Highly-Sensitive Detection of Beta-Amyloid 1\u201342","volume":"15","author":"Li","year":"2023","journal-title":"Nanoscale"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Sharma, P.K., Kim, E.-S., Mishra, S., Ganbold, E., Seong, R.-S., Kim, Y.M., Jahng, G.-H., Rhee, H.Y., Han, H.-S., and Kim, D.H. (2022). Ultrasensitive probeless capacitive biosensor for amyloid beta (A\u03b21-42) detection in human plasma using interdigitated electrodes. Biosens. Bioelectron., 212.","DOI":"10.1016\/j.bios.2022.114365"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"14061","DOI":"10.1038\/s41598-018-32250-3","article-title":"Time Course of Focused Ultrasound Effects on Beta-Amyloid Plaque Pathology in the TgCRND8 Mouse Model of Alzheimer\u2019s Disease","volume":"8","author":"Poon","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-021-00269-8","article-title":"Extensive frontal focused ultrasound mediated blood\u2013brain barrier opening for the treatment of Alzheimer\u2019s disease: A proof-of-concept study","volume":"10","author":"Park","year":"2021","journal-title":"Transl. Neurodegener."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nnano.2014.102","article-title":"Amyloid fibrils nucleated and organized by DNA origami constructions","volume":"9","author":"Udomprasert","year":"2014","journal-title":"Nat. Nanotechnol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41578-022-00517-x","article-title":"Functionalizing DNA origami to investigate and interact with biological systems","volume":"8","author":"Knappe","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100966","DOI":"10.1016\/j.apmt.2021.100966","article-title":"Bio-inspired amyloid polypeptides: From self-assembly to nanostructure design and biotechnological applications","volume":"22","author":"Lai","year":"2021","journal-title":"Appl. Mater. Today"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/YCO.0000000000000478","article-title":"Stem Cell Therapies for Alzheimer\u2019s Disease: Is It Time?","volume":"32","author":"Wang","year":"2019","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.4103\/1673-5374.274329","article-title":"Toxic tau: Structural origins of tau aggregation in Alzheimer\u2019s disease","volume":"15","author":"Uddin","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-180868","article-title":"Tau Abnormalities and the Potential Therapy in Alzheimer\u2019s Disease","volume":"67","author":"Almansoub","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"10595","DOI":"10.1523\/JNEUROSCI.1700-18.2018","article-title":"Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo","volume":"38","author":"Ondrejcak","year":"2018","journal-title":"J. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1007\/s12035-015-9369-x","article-title":"The Role of Cdk5 in Alzheimer\u2019s Disease","volume":"53","author":"Liu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fncel.2020.00019","article-title":"GSK3 Beta and Tau Protein in Alzheimer\u2019s Disease and Epilepsy","volume":"14","year":"2020","journal-title":"Front. Cell Neurosci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1212\/WNL.0000000000006875","article-title":"Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease","volume":"92","author":"Ossenkoppele","year":"2019","journal-title":"Neurology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET Imaging of Tau Deposition in the Aging Human Brain","volume":"89","author":"Lockhart","year":"2016","journal-title":"Neuron"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fneur.2015.00038","article-title":"PET Imaging of Tau Pathology in Alzheimer\u2019s Disease and Tauopathies","volume":"6","author":"James","year":"2015","journal-title":"Front. Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.15252\/emmm.201707809","article-title":"18F-AV-1451 and CSF T-Tau and P-Tau as Biomarkers in Alzheimer\u2019s Disease","volume":"9","author":"Mattsson","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/WCO.0000000000001035","article-title":"Overview of tau PET molecular imaging","volume":"35","author":"Petersen","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: Current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J. Intern. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","article-title":"CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease","volume":"91","author":"Janelidze","year":"2018","journal-title":"Neurology"},{"key":"ref_110","first-page":"18","article-title":"Biomarkers for tau pathology","volume":"97","author":"Maass","year":"2018","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41380-020-0721-9","article-title":"Biomarkers for Alzheimer\u2019s disease\u2014Preparing for a new era of disease-modifying therapies","volume":"26","author":"Zetterberg","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"942629","DOI":"10.3389\/fnagi.2022.942629","article-title":"Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"14","author":"Chen","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High Performance Plasma Amyloid-Beta Biomarkers for Alzheimer\u2019s Disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ana.24548","article-title":"Melanopsin Retinal Ganglion Cell Loss in Alzheimer Disease","volume":"79","author":"Koronyo","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaneurol.2018.1563","article-title":"Association of Retinal Neurodegeneration on Optical Coherence Tomography With Dementia A Population-Based Study","volume":"75","author":"Mutlu","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_120","first-page":"236","article-title":"Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer\u2019s Disease and Other Tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"19440","DOI":"10.1074\/jbc.M112.346072","article-title":"Trans-cellular Propagation of Tau Aggregation by Fibrillar Species","volume":"287","author":"Kfoury","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"101409","DOI":"10.1016\/j.arr.2021.101409","article-title":"The role of the immune system in Alzheimer\u2019s disease","volume":"70","author":"Wu","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"eaal2029","DOI":"10.1126\/scitranslmed.aal2029","article-title":"Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy","volume":"9","author":"Yanamandra","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_124","first-page":"e12179","article-title":"Alzheimer\u2019s Disease Drug Development Pipeline: 2021","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer\u2019s Dement Transl. Res. Clin. Interv."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","article-title":"Tau biomarkers in Alzheimer\u2019s disease: Towards implementation in clinical practice and trials","volume":"21","author":"Ossenkoppele","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.25406","article-title":"Longitudinal tau accumulation and atrophy in aging and alzheimer disease","volume":"85","author":"Harrison","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Medina, M. (2018). An Overview on the Clinical Development of Tau-Based Therapeutics. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041160"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","article-title":"Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease","volume":"26","author":"Dujardin","year":"2020","journal-title":"Nat. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s12035-022-03164-z","article-title":"Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders","volume":"60","author":"Kaur","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2174\/1389450120666191118123151","article-title":"Alzheimer\u2019s Disease Targeted Nano-Based Drug Delivery Systems","volume":"21","author":"Altinoglu","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2174\/1567201810666131113102037","article-title":"Preparation and characterization of methylene blue nanoparticles for Alzheimer\u2019s disease and other tauopathies","volume":"11","author":"Jinwal","year":"2013","journal-title":"Curr. Drug Deliv."},{"key":"ref_134","first-page":"1","article-title":"Neuron Tau-Targeting Biomimetic Nanoparticles for Curcumin Delivery to Delay Progression of Alzheimer\u2019s Disease","volume":"18","author":"Gao","year":"2020","journal-title":"J. Nanotechnol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"23328","DOI":"10.1021\/acsami.1c00257","article-title":"Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer\u2019s Disease","volume":"13","author":"Zhu","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/1028415X.2022.2084550","article-title":"Application of Curcumin Nanoformulations in Alzheimer\u2019s Disease: Prevention, Diagnosis and Treatment","volume":"26","author":"Lv","year":"2023","journal-title":"Nutr. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2019.10.034","article-title":"Nanoparticle-Mediated Approaches for Alzheimer\u2019s Disease Pathogenesis, Diagnosis, and Therapeutics","volume":"314","author":"Hettiarachchi","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"101388","DOI":"10.1016\/j.nantod.2022.101388","article-title":"Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer\u2019s Disease","volume":"43","author":"Xu","year":"2022","journal-title":"Nano Today"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-021-01138-1","article-title":"Systemic delivery of a specific antibody targeting the pathological N-terminal truncated tau peptide reduces retinal degeneration in a mouse model of Alzheimer\u2019s Disease","volume":"9","author":"Latina","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"100251","DOI":"10.1016\/j.impact.2020.100251","article-title":"Nanomaterials for the treatment and diagnosis of Alzheimer\u2019s disease: An overview","volume":"20","author":"Bilal","year":"2020","journal-title":"NanoImpact"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Xu, Y., Zhao, M., Zhou, D., Zheng, T., and Zhang, H. (2021). The application of multifunctional nanomaterials in Alzheimer\u2019s disease: A potential theranostics strategy. BioMedicine, 137.","DOI":"10.1016\/j.biopha.2021.111360"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Hoque, M., Samanta, A., Alam, S.S.M., Zughaibi, T.A., Kamal, M.A., and Tabrez, S. (2023). Nanomedicine-Based Immunotherapy for Alzheimer\u2019s Disease. Neurosci. Biobehav. Rev., 144.","DOI":"10.1016\/j.neubiorev.2022.104973"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-018-0046-8","article-title":"Prospects for strain-specific immunotherapy in Alzheimer\u2019s disease and tauopathies","volume":"3","author":"Bittar","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_144","first-page":"1","article-title":"A novel kit for early diagnosis of Alzheimer\u2019s disease using a fluorescent nanoparticle imaging","volume":"9","author":"Park","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"213659","DOI":"10.1016\/j.ccr.2020.213659","article-title":"Coordination chemistry of ligands: Insights into the design of amyloid beta\/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer\u2019s disease","volume":"430","author":"Selvan","year":"2020","journal-title":"Coord. Chem. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Oyarz\u00fan, M.P., Tapia-Arellano, A., Cabrera, P., Jara-Guajardo, P., and Kogan, M.J. (2021). Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer\u2019s Disease. Sensors, 21.","DOI":"10.3390\/s21062067"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.7150\/thno.72258","article-title":"A surrogate marker for very early-stage tau pathology is detectable by molecular magnetic resonance imaging","volume":"12","author":"Parekh","year":"2022","journal-title":"Theranostics"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"13657","DOI":"10.1039\/D2SC03932J","article-title":"Multipronged diagnostic and therapeutic strategies for Alzheimer\u2019s disease","volume":"13","author":"Ramesh","year":"2022","journal-title":"Chem. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2001945","DOI":"10.1002\/adma.202001945","article-title":"Fluorescent Diagnostic Probes in Neurodegenerative Diseases","volume":"32","author":"Zhou","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Phan, L.M.T., Hoang, T.X., Vo, T.A.T., Kim, J.Y., Lee, S.-M., Cho, W.W., Kim, Y.H., Choi, S.H., and Cho, S. (2020). Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimer\u2019s Disease. Diagnostics, 10.","DOI":"10.3390\/diagnostics10110913"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737159.2021.1887732","article-title":"Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer\u2019s Disease","volume":"21","author":"Phan","year":"2021","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijbiomac.2020.06.239","article-title":"Biosensors for detection of Tau protein as an Alzheimer\u2019s disease marker","volume":"162","author":"Ameri","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","article-title":"Gene-based therapies for neurodegenerative diseases","volume":"24","author":"Sun","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"134919","DOI":"10.1016\/j.neulet.2020.134919","article-title":"Targeting tau: Clinical trials and novel therapeutic approaches","volume":"731","author":"VandeVrede","year":"2020","journal-title":"Neurosci. Lett."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"580179","DOI":"10.3389\/fnins.2020.580179","article-title":"Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock","volume":"14","author":"Martier","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_156","first-page":"1","article-title":"Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease dementia: A systematic review","volume":"13","author":"Grueso","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_157","first-page":"1","article-title":"Machine Learning Techniques for the Diagnosis of Alzheimer\u2019s Disease: A Review","volume":"16","author":"Tanveer","year":"2020","journal-title":"ACM Trans. Multimedia Comput. Commun. Appl."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and Mitochondrial Cascades in Alzheimer\u2019s Disease","volume":"62","author":"Swerdlow","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/alz.12683","article-title":"The role of mitochondrial dysfunction in Alzheimer\u2019s disease pathogenesis","volume":"19","author":"Ashleigh","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Millichap, L.E., Damiani, E., Tiano, L., and Hargreaves, I.P. (2021). Targetable Pathways for Alleviating Mitochondrial Dysfunction in Neurodegeneration of Metabolic and Non-Metabolic Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111444"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/bs.irn.2020.01.008","article-title":"The Mitochondrial Hypothesis: Dysfunction, Bioenergetic Defects, and the Metabolic Link to Alzheimer\u2019s Disease","volume":"154","author":"Swerdlow","year":"2020","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2105607","DOI":"10.1155\/2019\/2105607","article-title":"Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View","volume":"2019","author":"Cenini","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","article-title":"Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease","volume":"20","author":"Butterfield","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2006.06.026","article-title":"Oxidative stress in Alzheimer\u2019s disease brain: New insights from redox proteomics","volume":"545","author":"Butterfield","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.mito.2021.10.008","article-title":"Blood biomarkers for assessment of mitochondrial dysfunction: An expert review","volume":"62","author":"Hubens","year":"2021","journal-title":"Mitochondrion"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00401-018-1868-1","article-title":"Alzheimer\u2019s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers","volume":"136","author":"Sinha","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","article-title":"Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study","volume":"11","author":"Fiandaca","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40824-023-00353-2","article-title":"Magnetic transferrin nanoparticles (MTNs) assay as a novel isolation approach for exosomal biomarkers in neurological diseases","volume":"27","author":"Jang","year":"2023","journal-title":"Biomater. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fphar.2015.00206","article-title":"A review on mitochondrial restorative mechanism of antioxidants in Alzheimer\u2019s disease and other neurological conditions","volume":"6","author":"Kumar","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"910289","DOI":"10.3389\/fnagi.2022.910289","article-title":"Investigation of coenzyme Q10 status, serum amyloid-\u03b2, and tau protein in patients with dementia","volume":"14","author":"Chang","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Shinn, L.J., and Lagalwar, S. (2021). Treating Neurodegenerative Disease with Antioxidants: Efficacy of the Bioactive Phenol Resveratrol and Mitochondrial-Targeted MitoQ and SkQ. Antioxidants, 10.","DOI":"10.20944\/preprints202102.0573.v1"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e55513","DOI":"10.7554\/eLife.55513","article-title":"Late-Life Restoration of Mitochondrial Function Reverses Cardiac Dysfunction in Old Mice","volume":"9","author":"Chiao","year":"2020","journal-title":"Elife"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-pharmtox-010715-103155","article-title":"Mitochondrial Biogenesis as a Pharmacological Target: A New Approach to Acute and Chronic Diseases","volume":"56","author":"Whitaker","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Yu, R., Liu, T., Jin, S.B., Ankarcrona, M., Lendahl, U., Nister, M., and Zhao, J. (2021). MIEF1\/2 Orchestrate Mitochondrial Dynamics through Direct Engagement with Both the Fission and Fusion Machineries. BMC Biol., 19.","DOI":"10.1186\/s12915-021-01161-7"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Kim, H., Lee, J.Y., Park, K.J., Kim, W.-H., and Roh, G.S. (2016). A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates kainic acid-induced hippocampal cell death. BMC Neurosci., 17.","DOI":"10.1186\/s12868-016-0270-y"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.tips.2022.11.004","article-title":"Mitochondrial dynamics proteins as emerging drug targets","volume":"44","author":"Zacharioudakis","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3389\/fphar.2019.00902","article-title":"Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update","volume":"10","author":"Cenini","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jalz.2007.07.002","article-title":"Mild Cognitive Impairment and Cognitive Impairment, No Dementia: Part B, Therapy","volume":"3","author":"Massoud","year":"2007","journal-title":"Alzheimers Dement."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1080\/15548627.2020.1810919","article-title":"Mitophagy coordination with retrograde transport ensures the integrity of synaptic mitochondria","volume":"16","author":"Han","year":"2020","journal-title":"Autophagy"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4252\/wjsc.v11.i5.236","article-title":"Modelling mitochondrial dysfunction in Alzheimer\u2019s disease using human induced pluripotent stem cells","volume":"11","author":"Hawkins","year":"2019","journal-title":"World J. Stem Cells"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"112536","DOI":"10.1016\/j.msec.2021.112536","article-title":"Delivery of coenzyme Q10 with mitochondria-targeted nanocarrier attenuates renal ischemia-reperfusion injury in mice","volume":"131","author":"Liu","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Thangudu, S., Cheng, F.-Y., and Su, C.-H. (2020). Advancements in the Blood\u2013Brain Barrier Penetrating Nanoplatforms for Brain Related Disease Diagnostics and Therapeutic Applications. Polymers, 12.","DOI":"10.3390\/polym12123055"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s13534-021-00198-5","article-title":"Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases","volume":"11","author":"Seo","year":"2021","journal-title":"Biomed. Eng. Lett."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Grabowska-Pyrzewicz, W., Want, A., Leszek, J., and Wojda, U. (2021). Antisense oligonucleotides for Alzheimer\u2019s disease therapy: From the mRNA to miRNA paradigm. EBioMedicine, 74.","DOI":"10.1016\/j.ebiom.2021.103691"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1038\/mtna.2015.15","article-title":"Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System","volume":"4","author":"Shyam","year":"2015","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Buchke, S., Sharma, M., Bora, A., Relekar, M., Bhanu, P., and Kumar, J. (2022). Mitochondria-Targeted, Nanoparticle-Based Drug-Delivery Systems: Therapeutics for Mitochondrial Disorders. Life, 12.","DOI":"10.3390\/life12050657"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Khan, T., Waseem, R., Zehra, Z., Aiman, A., Bhardwaj, P., Ansari, J., Hassan, I., and Islam, A. (2022). Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122657"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1111\/bph.14585","article-title":"Mitochondrial dysfunction in Alzheimer\u2019s disease: Role in pathogenesis and novel therapeutic opportunities","volume":"176","author":"Ortiz","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Chen, Z.-R., Huang, J.-B., Yang, S.-L., and Hong, F.-F. (2022). Role of Cholinergic Signaling in Alzheimer\u2019s Disease. Molecules, 27.","DOI":"10.3390\/molecules27061816"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Trzepacz, P.T., Hochstetler, H., Wang, S., Walker, B., and Saykin, A.J. (2015). Relationship between the Montreal Cognitive Assessment and Mini-mental State Examination for Assessment of Mild Cognitive Impairment in Llder Adults. BMC Geriatr., 15.","DOI":"10.1186\/s12877-015-0103-3"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13670-018-0234-4","article-title":"Recent Advances in Cholinergic Imaging and Cognitive Decline\u2014Revisiting the Cholinergic Hypothesis of Dementia","volume":"7","author":"Bohnen","year":"2018","journal-title":"Curr. Geriatr. Rep."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"704583","DOI":"10.3389\/fnagi.2021.704583","article-title":"CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment","volume":"13","author":"Karami","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"916020","DOI":"10.3389\/fnagi.2022.916020","article-title":"Large Margin and Local Structure Preservation Sparse Representation Classifier for Alzheimer\u2019s Magnetic Resonance Imaging Classification","volume":"14","author":"Liu","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"E12073","DOI":"10.1073\/pnas.1808507115","article-title":"Two distinct profiles of fMRI and neurophysiological activity elicited by acetylcholine in visual cortex","volume":"115","author":"Zaldivar","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.neuron.2013.10.017","article-title":"EEG and MEG: Relevance to Neuroscience","volume":"80","year":"2013","journal-title":"Neuron"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000330016","article-title":"A Review of Transcranial Magnetic Stimulation in the in vivo Functional Evaluation of Central Cholinergic Circuits in Dementia","volume":"32","author":"Nardone","year":"2011","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"201.e9","DOI":"10.1016\/j.neurobiolaging.2019.01.015","article-title":"Genetic screening in early-onset Alzheimer\u2019s disease identified three novel presenilin mutations","volume":"86","author":"Wong","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neuroscience.2016.08.009","article-title":"Central cholinergic pathway involvement in the regulation of pupil diameter, blink rate and cognitive function","volume":"334","author":"Naicker","year":"2016","journal-title":"Neuroscience"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/s41386-019-0397-5","article-title":"Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition","volume":"44","author":"Vallianatou","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_200","first-page":"1479","article-title":"Cholinesterase Inhibitors as Alzheimer\u2019s Therapeutics","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/ntr\/nty116","article-title":"Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer\u2019s Dementia: An Update","volume":"21","author":"Hoskin","year":"2018","journal-title":"Nicotine Tob. Res."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e13037","DOI":"10.1111\/acel.13037","article-title":"Lifelong choline supplementation ameliorates Alzheimer\u2019s disease pathology and associated cognitive deficits by attenuating microglia activation","volume":"18","author":"Velazquez","year":"2019","journal-title":"Aging Cell"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4252\/wjsc.v12.i8.787","article-title":"Stem cell therapy for Alzheimer\u2019s disease","volume":"12","author":"Liu","year":"2020","journal-title":"World J. Stem Cells"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Kabir, T., Uddin, S., Al Mamun, A., Jeandet, P., Aleya, L., Mansouri, R.A., Ashraf, G.M., Mathew, B., Bin-Jumah, M.N., and Abdel-Daim, M.M. (2020). Combination Drug Therapy for the Management of Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093272"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2174\/1381612828666211222163025","article-title":"Drug Delivery Systems and Strategies to Overcome the Barriers of Brain","volume":"28","author":"Garg","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Teixeira, M.I., Lopes, C.M., Amaral, M.H., and Costa, P.C. (2023). Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases. Colloids Surf. B Biointerfaces, 221.","DOI":"10.1016\/j.colsurfb.2022.112999"},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Riccardi, C., Napolitano, F., Montesarchio, D., Sampaolo, S., and Melone, M.A.B. (2021). Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111897"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/elan.201700836","article-title":"Microelectrode Biosensors for Invivo Analysis of Brain Interstitial Fluid","volume":"30","author":"Chatard","year":"2018","journal-title":"Electroanalysis"},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Ardakani, T., Hosu, O., Cristea, C., Ardakani, M., and Marrazza, G. (2019). Latest Trends in Electrochemical Sensors for Neurotransmitters: A Review. Sensors, 19.","DOI":"10.3390\/s19092037"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e2103208","DOI":"10.1002\/adma.202103208","article-title":"Nanotechnology Enables Novel Modalities for Neuromodulation","volume":"33","author":"Yang","year":"2021","journal-title":"Adv. Mater."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneumeth.2017.12.001","article-title":"Nanoelectronics enabled chronic multimodal neural platform in a mouse ischemic model","volume":"295","author":"Luan","year":"2018","journal-title":"J. Neurosci. Methods"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Tarricone, G., Carmagnola, I., and Chiono, V. (2022). Tissue-Engineered Models of the Human Brain: State-of-the-Art Analysis and Challenges. J. Funct. Biomater., 13.","DOI":"10.3390\/jfb13030146"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.nano.2015.06.003","article-title":"Movement of magnetic nanoparticles in brain tissue: Mechanisms and impact on normal neuronal function","volume":"11","author":"Ramaswamy","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4103\/1673-5374.353484","article-title":"Targeting neuroinflammation in Alzheimer\u2019s disease: From mechanisms to clinical applications","volume":"18","author":"Liu","year":"2022","journal-title":"Neural Regen. Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuroscience.2014.09.061","article-title":"Neuroinflammation in Alzheimer\u2019s disease; A source of heterogeneity and target for personalized therapy","volume":"302","author":"Latta","year":"2014","journal-title":"Neuroscience"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"739130","DOI":"10.3389\/fimmu.2021.739130","article-title":"PET Imaging of Neuroinflammation in Alzheimer\u2019s Disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/ejn.15613","article-title":"Neuroinflammation PET imaging of the translocator protein (TSPO) in Alzheimer\u2019s disease: An update","volume":"55","author":"Gouilly","year":"2022","journal-title":"Eur. J. Neurosci."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1474-4422(20)30346-X","article-title":"PET imaging of neuroinflammation in neurological disorders","volume":"19","author":"Kreisl","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_219","first-page":"221","article-title":"MicroRNAs: Roles in Regulating Neuroinflammation","volume":"24","author":"Gaudet","year":"2017","journal-title":"Neurosci."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Giallongo, S., Longhitano, L., Denaro, S., D\u2019aprile, S., Torrisi, F., La Spina, E., Giallongo, C., Mannino, G., Furno, D.L., and Zappal\u00e0, A. (2022). The Role of Epigenetics in Neuroinflammatory-Driven Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315218"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3233\/JAD-210147","article-title":"Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimer\u2019s and Lewy Body Diseases","volume":"82","author":"Lourenco","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41380-022-01878-z","article-title":"Neuroinflammation is independently associated with brain network dysfunction in Alzheimer\u2019s disease","volume":"28","author":"Leng","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Kamagata, K., Andica, C., Kato, A., Saito, Y., Uchida, W., Hatano, T., Lukies, M., Ogawa, T., Takeshige-Amano, H., and Akashi, T. (2021). Diffusion Magnetic Resonance Imaging-Based Biomarkers for Neurodegenerative Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105216"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/gerona\/glab282","article-title":"Elevated C-Reactive Protein in Alzheimer\u2019s Disease Without Depression in Older Adults: Findings From the Health and Retirement Study","volume":"77","author":"Natale","year":"2021","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"100149","DOI":"10.1016\/j.crphar.2022.100149","article-title":"Role of pro-inflammatory cytokines in Alzheimer\u2019s disease and neuroprotective effects of pegylated self-assembled nanoscaffolds","volume":"4","author":"Rani","year":"2023","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Gaetani, L., Bellomo, G., Parnetti, L., Blennow, K., Zetterberg, H., and Di Filippo, M. (2021). Neuroinflammation and Alzheimer\u2019s Disease: A Machine Learning Approach to CSF Proteomics. Cells, 10.","DOI":"10.3390\/cells10081930"},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Seo, Y., Jang, H., and Lee, H. (2022). Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer\u2019s Disease. Life, 12.","DOI":"10.3390\/life12020275"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/CIA.S357558","article-title":"Neuroinflammation as a Potential Therapeutic Target in Alzheimer\u2019s Disease","volume":"17","author":"Liu","year":"2022","journal-title":"Clin. Interv. Aging"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"17562864231156674","DOI":"10.1177\/17562864231156674","article-title":"Microglia as a cellular target of diclofenac therapy in Alzheimer\u2019s disease","volume":"16","author":"Stopschinski","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Kasindi, A., Fuchs, D.-T., Koronyo, Y., Rentsendorj, A., Black, K.L., and Koronyo-Hamaoui, M. (2022). Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. Cells, 11.","DOI":"10.3390\/cells11091578"},{"key":"ref_231","first-page":"80","article-title":"Anti-Inflammatory and Cognitive Effects of Interferon-Beta 1a (IFN Beta 1a) in a Rat Model of Alzheimer\u2019s Disease","volume":"227","author":"Frinchi","year":"2019","journal-title":"Acta Physiol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.yfrne.2019.100788","article-title":"Neurosteroids as regulators of neuroinflammation","volume":"55","author":"Karali","year":"2019","journal-title":"Front. Neuroendocrinol."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Althafar, Z.M. (2022). Targeting Microglia in Alzheimer\u2019s Disease: From Molecular Mechanisms to Potential Therapeutic Targets for Small Molecules. Molecules, 27.","DOI":"10.3390\/molecules27134124"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000528036","article-title":"The Immunomodulatory Potential Role of Mesenchymal Stem Cells in Diseases of the Central Nervous System","volume":"22","author":"Rufino","year":"2022","journal-title":"Neurodegener. Dis."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ame2.12207","article-title":"Stem cell therapy for Alzheimer\u2019s disease: An overview of experimental models and reality","volume":"5","author":"Qin","year":"2022","journal-title":"Anim. Model. Exp. Med."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10517-018-4128-4","article-title":"Therapeutic Effects of Repetitive Transcranial Magnetic Stimulation (RTMS) on Neuroinflammation and Neuroplasticity in Patients with Parkinson\u2019s Disease: A Placebo-Controlled Study","volume":"165","author":"Aftanas","year":"2018","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1007\/s00415-022-11236-2","article-title":"Transcranial magnetic stimulation treatment in Alzheimer\u2019s disease: A meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization","volume":"269","author":"Menardi","year":"2022","journal-title":"J. Neurol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/npjamd.2016.12","article-title":"Amyloid Proteotoxicity Initiates an Inflammatory Response Blocked by Cannabinoids","volume":"2","author":"Currais","year":"2016","journal-title":"NPJ Aging Mech. Dis."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Abate, G., Uberti, D., and Tambaro, S. (2021). Potential and Limits of Cannabinoids in Alzheimer\u2019s Disease Therapy. Biology, 10.","DOI":"10.3390\/biology10060542"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13668-019-0271-4","article-title":"Diet and Inflammation in Cognitive Ageing and Alzheimer\u2019s Disease","volume":"8","author":"McGrattan","year":"2019","journal-title":"Curr. Nutr. Rep."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-150505","article-title":"A Role for Complementary and Integrative Medicine in Alzheimer\u2019s Disease Prevention","volume":"48","author":"Ashford","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M.A., Abujabal, K.A., Faqih, Y.A.H., Rashid, H., Rashid, S.M., and Ahmad, S.B. (2023). The Future of Precision Medicine in the Cure of Alzheimer\u2019s Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020335"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"APMI, Hampel, H., Caraci, F., Cuello, A.C., Caruso, G., Nistico, R., Corbo, M., Baldacci, F., Toschi, N., and Garaci, F. (2020). A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer\u2019s Disease. Front. Immunol., 11, 456.","DOI":"10.3389\/fimmu.2020.00456"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnmol.2018.00164","article-title":"Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics","volume":"11","author":"Abreu","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Zhao, N.X., Francis, N.L., Calvelli, H.R., and Moghe, P.V. (2020). Microglia-Targeting Nanotherapeutics for Neurodegenerative Diseases. APL Bioengineering, 4.","DOI":"10.1063\/5.0013178"},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Siafaka, P.I., Okur, M.E., Erim, P.D., Caglar, E.S., Ozgenc, E., Gundogdu, E., Koprulu, R.E.P., Karantas, I.D., and Okur, N.U. (2022). Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112425"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/3476476","article-title":"In Vivo MRI of Functionalized Iron Oxide Nanoparticles for Brain Inflammation","volume":"2018","author":"Tang","year":"2018","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"683935","DOI":"10.3389\/fphar.2021.683935","article-title":"Nanoparticles: A Hope for the Treatment of Inflammation in CNS","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"576037","DOI":"10.3389\/fncel.2020.576037","article-title":"Neuroinflammation Treatment via Targeted Delivery of Nanoparticles","volume":"14","author":"Cerqueira","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"ref_250","first-page":"666","article-title":"Applications of nanotechnology in drug delivery to the central nervous system","volume":"111","author":"Saeedi","year":"2019","journal-title":"BioMedicine"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.biomaterials.2014.08.039","article-title":"A strategy to passively reduce neuroinflammation surrounding devices implanted chronically in brain tissue by manipulating device surface permeability","volume":"36","author":"Skousen","year":"2015","journal-title":"Biomaterials"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhou, J., Gu, Z., Zhang, H., Gong, Q., and Luo, K. (2020). Advances in nanomedicines for diagnosis of central nervous system disorders. Biomaterials, 269.","DOI":"10.1016\/j.biomaterials.2020.120492"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.mattod.2021.09.014","article-title":"Functional nanomaterials in peripheral nerve regeneration: Scaffold design, chemical principles and microenvironmental remodeling","volume":"51","author":"Qian","year":"2021","journal-title":"Mater. Today"},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Teleanu, R.I., Gherasim, O., Gherasim, T.G., Grumezescu, V., Grumezescu, A.M., and Teleanu, D.M. (2019). Nanomaterial-Based Approaches for Neural Regeneration. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11060266"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26599\/JNR.2022.9040001","article-title":"Nanoparticles in peripheral nerve regeneration: A mini review","volume":"10","author":"Javed","year":"2022","journal-title":"J. Neurorestoratol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/23\/2669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:38Z","timestamp":1760131538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/23\/2669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":255,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cells12232669"],"URL":"https:\/\/doi.org\/10.3390\/cells12232669","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]}}}